Loading...
Yestar Healthcare Holdings Company Limited
2393.HK•HKSE
Healthcare
Medical - Devices
HK$0.19
HK$0.007(3.87%)

Over the last four quarters, Yestar Healthcare Holdings Company Limited achieved steady financial progress, growing revenue from $1.97B in Q2 2022 to $1.27B in Q2 2024. Gross profit stayed firm with margins at 17% in Q2 2024 versus 15% in Q2 2022. Operating income totaled $51.73M in Q2 2024, maintaining a 4% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $75.35M. Net income rose to $1.09B, with EPS at $0.47. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan